More Magnesium needed by obese (Mg Sulfate, women in this case) – RCT Dec 2021

Alternate Dosing Protocol for Magnesium Sulfate in Obese Women With Preeclampsia: A Randomized Controlled Trial

Clinical Trial Obstet Gynecol. 2020 Dec;136(6):1190-1194. doi: 10.1097/AOG.0000000000004137.
Kathleen F Brookfield 1, Kierstyn Tuel, Monica Rincon, Abbie Vinson, Aaron B Caughey, Brendan Carvalho

Objective: To evaluate whether obese women need greater doses of magnesium sulfate to obtain therapeutic serum concentrations for eclamptic seizure prevention.

Methods: Women with preeclampsia and a body mass index (BMI) of 35 or higher were randomly allocated to either the Zuspan regimen of magnesium sulfate (4-g intravenous IV loading dose, then a 1-g/h infusion) or to alternate dosing (6-g IV loading dose, then a 2-g/h infusion). Women had serum magnesium concentrations obtained at baseline, as well as after administration of magnesium sulfate at 1 hour, 4 hours, and delivery. The primary outcome was the proportion of women who had subtherapeutic serum magnesium concentrations (less than 4.8 mg/dL) 4 hours after administration. A sample size of 18 women per group was planned to compare the proportion of women with subtherapeutic serum magnesium concentrations in each group.

Results: From July 12, 2016, to March 14, 2019, 89 women with preeclampsia were screened and 37 were enrolled: 18 to the Zuspan regimen and 19 to the alternate regimen. A significantly greater proportion of women administered the Zuspan regimen had subtherapeutic serum magnesium concentrations at 4 hours (100% [95% CI 59-100] vs 63% [95% CI 41-81]; P=.01) compared with women administered the alternate higher dose regimen. At 4 hours, mean concentrations were significantly higher in the alternate regimen group (3.53 mg/dL±0.3 [Zuspan regimen] vs 4.41±0.5 [alternate regimen]; P<.01).

Conclusion: The alternate dosing regimen of a 6-g IV loading dose followed by a 2-g/h IV maintenance dose more reliably achieves therapeutic serum magnesium concentrations (as defined by a concentration of at least 4.8 mg/dL) in obese women with preeclampsia.

Clinical trial registration: ClinicalTrials.gov, NCT02835339.

See also VitaminDWiki

Magnesium and Vitamin D contains the following highlights

365 items in category, see also

Mg and Vitamin D

Magnesium topics gathered on a page


Overview Magnesium and vitamin D Has a venn diagram of relationship of Mg and Vit D

 Magnesiumnot Magnesium
Vitamin D Magnesium or Vitamin D
Aging, Amyotrophic Lateral Sclerosis, Alzheimer's Disease;
Asthma, Attention Deficit Disorder, Autism, Cancer, Cerebrovascular,
Chronic Fatigue, Diabetes, Hearing Loss, Heart Disease, Heart Attack, Atherosclerosis,
Cardiovascular Disease, HIV, AIDS; Hypertension; Kidney Stones,
Migraine Headache, Multiple Sclerosis, Obesity, Osteoporosis, Peripheral vascular disease;
Pregnancy-related problems, Rheumatoid Arthritis, Sports-related problems,		Vitamin D only
Acne, Allergy, Autoimmune, Bone, Breathing,
Celiac, Cognition, Colds and Flu, Cystic Fibrosis,
Dental, Fertility, hyperparathyroid, Immunity, Kidney,
Liver, Lupus, Osteoarthritis, Pain - chronic, Parkinson,
Psoriasis, Rickets, Strokes, Sarcoidosis, Thyroid, Parathyroid,
Tuberculosis, Vision, Hair, Skin, Sports
Not Vitamin DMagnesium only
Aggressive Behavior, Alcoholism, Arrhythmia, Cerebral Palsy,
Chemical Sensitivity, Cluster Headaches; Cocaine-related Stroke; Constipation,
Cramps, Fluoride Toxicity, Head Injuries, Central Nervous System Injuries,
Magnesium Deficiency; Menopause, Mitral Valve Prolapse,
Nystagmus, Psychiatric Disorders; Repetitive Strain Injury, Sickle Cell Disease, SIDS,
Stress, Stuttering, Tetanus; Tinnitus, Sound Sensitivity; TMJ; Toxic Shock; Violence		Neither
ALL OTHER DISEASES


Magnesium Miracle, 2nd edition - Aug 2017

VitaminDWiki - 11 studies in both categories Obesity and Magnesium

This list is automatically updated

2746 visitors, last modified 03 Aug, 2022,
Printer Friendly Follow this page for updates